{"id":"anti-thymocyte-globulins-treatment","safety":{"commonSideEffects":[{"rate":"60–90%","effect":"Fever and chills"},{"rate":"50–80%","effect":"Thrombocytopenia"},{"rate":"50–80%","effect":"Leukopenia"},{"rate":"10–30%","effect":"Serum sickness"},{"rate":"20–40%","effect":"Infection (opportunistic)"},{"rate":"1–5%","effect":"Anaphylaxis"},{"rate":"10–20%","effect":"Lymphadenopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATG is a polyclonal antibody preparation derived from immunized animals (typically rabbits or horses) that targets multiple antigens on the surface of T cells. Upon binding, it activates complement-mediated lysis and antibody-dependent cellular cytotoxicity, leading to rapid T-cell depletion. This profound immunosuppression is used to prevent graft rejection in transplantation and to treat T-cell mediated autoimmune conditions.","oneSentence":"Anti-thymocyte globulin (ATG) depletes T lymphocytes by binding to T-cell antigens and triggering their destruction, thereby suppressing the adaptive immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:27.934Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in allogeneic transplantation (renal, cardiac, hepatic)"},{"name":"Treatment of aplastic anemia"},{"name":"Graft-versus-host disease (GVHD) prophylaxis and treatment"}]},"trialDetails":[{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07061574","phase":"PHASE1, PHASE2","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-30","conditions":"Type 1 Diabetes, New Onset","enrollment":120},{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":"AML, ALL, MDS","enrollment":31},{"nctId":"NCT06365437","phase":"PHASE2","title":"A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2021-06-06","conditions":"Kidney Transplantation","enrollment":33},{"nctId":"NCT03980769","phase":"PHASE2","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-05","conditions":"Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder","enrollment":40},{"nctId":"NCT04862221","phase":"PHASE2","title":"TReatment for ImmUne Mediated PathopHysiology","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2022-02-09","conditions":"Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy","enrollment":163},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT04965597","phase":"PHASE2","title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-04-19","conditions":"Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia","enrollment":40},{"nctId":"NCT04304820","phase":"PHASE2","title":"Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2020-05-07","conditions":"Severe Aplastic Anemia","enrollment":80},{"nctId":"NCT06055608","phase":"PHASE2","title":"Advancing Transplantation Outcomes in Children","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-22","conditions":"Kidney Transplant","enrollment":200},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT05156710","phase":"PHASE2","title":"BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-09","conditions":"Transplant Rejection","enrollment":48},{"nctId":"NCT07284641","phase":"PHASE2","title":"Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2026-03-01","conditions":"Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation","enrollment":25},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT06075706","phase":"PHASE2","title":"Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"medac GmbH","startDate":"2023-11-13","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":48},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT05669001","phase":"PHASE2","title":"A Study of TCD601 in de Novo Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITB-Med LLC","startDate":"2023-12-28","conditions":"Renal Transplantation","enrollment":76},{"nctId":"NCT04328727","phase":"PHASE2","title":"Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-04","conditions":"Severe Aplastic Anemia (SAA)","enrollment":36},{"nctId":"NCT07338422","phase":"NA","title":"HID-HSCT Versus IST as First-line Treatment for SAA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-01-14","conditions":"Aplastic Anaemia","enrollment":116},{"nctId":"NCT02171104","phase":"PHASE2","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-07-10","conditions":"Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome","enrollment":149},{"nctId":"NCT01746849","phase":"PHASE2","title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Leukemia, Multiple Myeloma, Myelodysplastic Syndrome","enrollment":82},{"nctId":"NCT04395222","phase":"PHASE2","title":"Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-07","conditions":"Hematologic Malignancy, Bone Marrow Transplant","enrollment":21},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT05757310","phase":"PHASE1","title":"A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-11-15","conditions":"Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia","enrollment":6},{"nctId":"NCT07297550","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-15","conditions":"Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia","enrollment":42},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT07001254","phase":"PHASE2","title":"UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Anjali Sharathkumar","startDate":"2026-08-01","conditions":"Aplastic Anemia","enrollment":15},{"nctId":"NCT04083183","phase":"PHASE1, PHASE2","title":"Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-06-16","conditions":"Non-Malignant Neoplasm","enrollment":40},{"nctId":"NCT06430788","phase":"PHASE2","title":"A Study of Emapalumab for Pediatric Aplastic Anemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-05-21","conditions":"Aplastic Anemia, Cytopenia, Hypocellular Marrow","enrollment":35},{"nctId":"NCT03622788","phase":"PHASE1, PHASE2","title":"Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia","enrollment":16},{"nctId":"NCT06455319","phase":"PHASE2","title":"Precision Administration of Anti-thymocyte Globulin With or Without Verapamil","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-11-12","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT06039020","phase":"","title":"ATGAM General Investigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-02-21","conditions":"Aplastic Anemia","enrollment":1},{"nctId":"NCT02727803","phase":"PHASE2","title":"Personalized NK Cell Therapy in CBT","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-19","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT02323867","phase":"PHASE2","title":"Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2014-10","conditions":"Leukemia, Lymphoma, Myelodysplasia","enrollment":140},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84},{"nctId":"NCT03630211","phase":"PHASE2","title":"Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-07-31","conditions":"Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease","enrollment":8},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT01624805","phase":"PHASE2","title":"Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-25","conditions":"Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":140},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT02512497","phase":"PHASE1","title":"Romidepsin Maintenance After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2017-12-08","conditions":"Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia","enrollment":23},{"nctId":"NCT04872595","phase":"PHASE2","title":"A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-30","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Myelodysplastic Syndromes (MDS)","enrollment":59},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT03531736","phase":"PHASE1","title":"T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-09","conditions":"Myeloid Diseases","enrollment":17},{"nctId":"NCT04629833","phase":"PHASE3","title":"Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy","status":"RECRUITING","sponsor":"medac GmbH","startDate":"2021-08-16","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":210},{"nctId":"NCT02790515","phase":"PHASE2","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-07-14","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma","enrollment":170},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT04558736","phase":"PHASE2","title":"Haploidentical HCT for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-01-21","conditions":"Aplastic Anemia, Bone Marrow Failure Syndrome","enrollment":21},{"nctId":"NCT02722668","phase":"PHASE2","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-15","conditions":"Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma","enrollment":15},{"nctId":"NCT04098393","phase":"PHASE1","title":"Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-09-18","conditions":"Hematologic Malignancies","enrollment":39},{"nctId":"NCT04530487","phase":"PHASE2","title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-19","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor","enrollment":1},{"nctId":"NCT05132166","phase":"PHASE2","title":"A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-12-22","conditions":"Graft Vs Host Disease","enrollment":50},{"nctId":"NCT06674382","phase":"NA","title":"Haplo-HSCT for Myelofibrosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-01-01","conditions":"Myelofibrosis","enrollment":39},{"nctId":"NCT02845596","phase":"NA","title":"Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Michael Pulsipher","startDate":"2016-08","conditions":"Severe Aplastic Anemia","enrollment":40},{"nctId":"NCT02162420","phase":"NA","title":"Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2015-01-10","conditions":"Dyskeratosis Congenita, Aplastic Anemia","enrollment":61},{"nctId":"NCT05996393","phase":"PHASE4","title":"CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2023-09-15","conditions":"Aplastic Anemia","enrollment":86},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT02766465","phase":"PHASE2","title":"Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-03-16","conditions":"Sickle Cell Disease","enrollment":138},{"nctId":"NCT03615105","phase":"PHASE2","title":"Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-25","conditions":"Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)","enrollment":9},{"nctId":"NCT06904131","phase":"NA","title":"A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors","status":"RECRUITING","sponsor":"Obstetrics & Gynecology Hospital of Fudan University","startDate":"2025-05-11","conditions":"Gynecological Solid Tumors","enrollment":20},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT01758328","phase":"PHASE1","title":"Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT01623167","phase":"PHASE1, PHASE2","title":"Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2012-07-02","conditions":"Severe Aplastic Anemia","enrollment":207},{"nctId":"NCT03025698","phase":"PHASE2","title":"A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-30","conditions":"Aplastic Anemia","enrollment":51},{"nctId":"NCT01701986","phase":"PHASE1, PHASE2","title":"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-25","conditions":"Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":64},{"nctId":"NCT04311632","phase":"PHASE2","title":"A Dose Escalation Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"ITB-Med LLC","startDate":"2021-05-26","conditions":"Kidney Transplantation","enrollment":13},{"nctId":"NCT02274662","phase":"PHASE4","title":"Expanded Access Protocol Thymus Transplantation","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2014-08","conditions":"Poor Thymic Function, Immunodeficiency, Athymia","enrollment":11},{"nctId":"NCT01413100","phase":"PHASE2","title":"Scleroderma Treatment With Autologous Transplant (STAT) Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-09-15","conditions":"Systemic Scleroderma","enrollment":21},{"nctId":"NCT03318159","phase":"PHASE2","title":"Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-04-20","conditions":"Aplastic Anemia, Myelodysplastic Syndromes, Fungal Infection","enrollment":20},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT01019876","phase":"PHASE2, PHASE3","title":"Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09","conditions":"Bone Marrow Failure, Osteopetrosis, Fanconi Anemia","enrollment":38},{"nctId":"NCT04521946","phase":"PHASE1","title":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-14","conditions":"Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Germ Cell Tumor","enrollment":""},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT05743400","phase":"PHASE4","title":"Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-09-25","conditions":"Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy","enrollment":35},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT04302805","phase":"PHASE3","title":"rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2020-07-27","conditions":"Kidney Transplantation","enrollment":17},{"nctId":"NCT01664910","phase":"PHASE1, PHASE2","title":"CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-29","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":27},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT03606746","phase":"PHASE2","title":"Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants","status":"WITHDRAWN","sponsor":"Medeor Therapeutics, Inc.","startDate":"2024-12","conditions":"Kidney Transplant Rejection","enrollment":""},{"nctId":"NCT05832515","phase":"PHASE1","title":"AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2020-10-01","conditions":"Multiple Sclerosis","enrollment":200},{"nctId":"NCT01033552","phase":"PHASE1, PHASE2","title":"Biochemical Correction of Severe EB by Allo HSCT and \"Off-the-shelf\" MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2010-01","conditions":"Epidermolysis Bullosa","enrollment":32},{"nctId":"NCT00003552","phase":"PHASE1, PHASE2","title":"Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-01","conditions":"Stage IV Melanoma, Recurrent Melanoma","enrollment":""},{"nctId":"NCT04936971","phase":"PHASE4","title":"Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response","status":"WITHDRAWN","sponsor":"Edoardo Melilli","startDate":"2021-09","conditions":"Kidney Transplantation, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT04418414","phase":"PHASE1","title":"Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Expression Therapeutics, LLC","startDate":"2024-09-01","conditions":"Hemophilia A","enrollment":7},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT02464878","phase":"PHASE2","title":"Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"Kidney Transplant, Type 1 Diabetes","enrollment":2},{"nctId":"NCT00579371","phase":"PHASE1, PHASE2","title":"Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2004-03-17","conditions":"Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT03734601","phase":"PHASE2","title":"Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Stanford University","startDate":"2018-11-05","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder","enrollment":22},{"nctId":"NCT04203017","phase":"PHASE1","title":"Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis","status":"TERMINATED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2019-06-01","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT01994824","phase":"PHASE2","title":"Preemptive Therapy of GVHD","status":"TERMINATED","sponsor":"University of Calgary","startDate":"2014-01","conditions":"Graft-vs-host Disease","enrollment":70},{"nctId":"NCT03943238","phase":"PHASE1","title":"TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation","status":"UNKNOWN","sponsor":"Stanford University","startDate":"2020-02-01","conditions":"Living Donor Kidney Transplantation","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3194,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Anti-Thymocyte Globulins treatment","genericName":"Anti-Thymocyte Globulins treatment","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-thymocyte globulin (ATG) depletes T lymphocytes by binding to T-cell antigens and triggering their destruction, thereby suppressing the adaptive immune response. Used for Prevention of acute organ rejection in allogeneic transplantation (renal, cardiac, hepatic), Treatment of aplastic anemia, Graft-versus-host disease (GVHD) prophylaxis and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}